PMC10073548_01
Comparison of computed tomography images before and after treatment with ensartinib.
fonc-13-1084456-g001.jpg
PMC10073548_01_fonc-13-1084456-g001.jpg
f1
Enhanced computed tomography (CT) scans of the abdomen revealed an abdominal mass that was suspected to be gastric stromal tumor ( Figure 1  and  Table 1 ). The therapeutic course and radiological examinations of the patient were summarized in  Figure 1 . In September 29, 2022, 4 months after initiation of ensartinib, this patient still achieved partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 ( Figure 1 ).
Histopathological examination with haematoxylin and eosin staining and Immunohistochemistry and FISH images. The lesion consisted of both epithelioid and spindle cells with enlarged nucleolus and inflammatory cells infiltration (A) (magnification, x40). (B) (magnification, x200). (C) ALK positivity (magnification, x400); (D)Focal CD30 weakly positive (magnification, x400); (E)Desmin positivity (magnification, x400) (F)SMA positivity (magnification, x400) (G) Vimentin positivity (magnification, x400); (H) A FISH image of ALK rearrangement.
fonc-13-1084456-g002.jpg
PMC10073548_01_fonc-13-1084456-g002.jpg
f2
The histopathological results revealed the lesion contained both epithelioid and spindle cells with enlarged nuclei and infiltrating inflammatory cells, primarily plasma cells, eosinophils, neutrophils, lymphocytes ( Figures 2A, B ). ALK-IHC is ALK p80(5A4), and Positive immunohistochemical results of ALK, CD30, desmin, SAM and Vimentin are shown in turn in this  Figures 2C-G . Approximately 18% of the tumor cells showed a rearrangement of ALK by FISH ( Figure 2H ).